Brenipatide

Eli Lilly · LY3537031

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
16 active
19 in total · 5 in the EU
Targets
 

What this is

How it works
Copies two gut hormones, GLP-1 and GIP, to lower appetite and blood sugar. Same approach as Mounjaro and Zepbound.GIP/GLP-1 receptor dual agonist
Tested for
Depressive Disorder, Major (2 trials), Alcohol Use Disorder (2 trials), Irritable Bowel Syndrome (2 trials), Overweight (2 trials), Obesity (2 trials), Smoking, Constipation, Diarrhea and 7 more
Main trialPhase 3
“This study evaluates the safety and efficacy of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC in delaying the return of major depressive symptoms. The trial is divided into four periods as follows: a screening period that will last approximately 1 month, a treatment period with a potential post treatment period that combined will last a minimum of 12 months, and the follow up period that will last approximately 2 months.”In the company’s words, NCT07412756 on ClinicalTrials.gov
Other names
LY3537031

Other drugs for Depressive Disorder, Major

All 36 drugs for Depressive Disorder, Major

Coming up12

Changes1

Last 90 days

Trials19

TrialPhaseCompletesWhat it tests
Phase 3Recruiting Feb 2028 A Study of Brenipatide in Adult Participants With Major Depressive Disorder
Phase 3Recruiting Apr 2028 A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder
Phase 3Recruiting Apr 2028 A Study of Brenipatide in Participants With Alcohol Use Disorder
Phase 3Recruiting Dec 2028 A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
Phase 2Recruiting Feb 2027 A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse
Phase 2Recruiting Jul 2027 A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)
Phase 2Recruiting Sep 2027 A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)
Phase 2Recruiting Nov 2027 A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)
Phase 2Recruiting Nov 2027 A Study of Brenipatide in Adult Participants With Schizophrenia
Phase 2Recruiting Mar 2028 A Study of Brenipatide in Participants With Opioid Use Disorder
Phase 2Recruiting Apr 2028 A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
Phase 2Not yet recruiting May 2028 A Study of Brenipatide in Participants With Major Depressive Disorder
Phase 2Recruiting May 2028 A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
Phase 1Recruiting Nov 2026 A Study of the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver Impairment
Phase 1Active, not recruiting Nov 2026 A Study of LY3537031 in Overweight, Obese, and Healthy Participants
Phase 1Active, not recruiting Feb 2027 A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or Obesity
Phase 1Completed 4 Jun 2021 A Study of LY3537031 in Healthy Participants
Phase 1Completed 16 Apr 2026 A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment
Phase 1Completed 17 Jul 2026 A Study of How the Body Absorbs LY3537031
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Brenipatide

Following is part of Solo: you see every change to Brenipatide the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in